Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NASDAQ:NGEN NASDAQ:RGNX NASDAQ:RLMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$2.82+0.4%$2.89$2.56▼$6.44$546.47M0.254.16 million shs1.98 million shsNGENNervGen Pharma$1.78+2.9%$2.19$1.59▼$6.30$143.52MN/A509,532 shs680,728 shsRGNXREGENXBIO$10.34+0.2%$9.10$5.45▼$16.19$533.52M0.92.68 million shs1.98 million shsRLMDRelmada Therapeutics$5.30+6.0%$6.54$0.55▼$8.00$524.45M0.412.47 million shs2.67 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+0.36%-3.75%+4.44%-18.73%-30.37%NGENNervGen Pharma+2.89%+2.30%-19.09%+177,999,900.00%+177,999,900.00%RGNXREGENXBIO+0.19%-15.87%+32.56%+10.71%+21.79%RLMDRelmada Therapeutics+6.00%-14.65%-21.25%-24.93%+763.19%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$2.82+0.4%$2.89$2.56▼$6.44$546.47M0.254.16 million shs1.98 million shsNGENNervGen Pharma$1.78+2.9%$2.19$1.59▼$6.30$143.52MN/A509,532 shs680,728 shsRGNXREGENXBIO$10.34+0.2%$9.10$5.45▼$16.19$533.52M0.92.68 million shs1.98 million shsRLMDRelmada Therapeutics$5.30+6.0%$6.54$0.55▼$8.00$524.45M0.412.47 million shs2.67 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+0.36%-3.75%+4.44%-18.73%-30.37%NGENNervGen Pharma+2.89%+2.30%-19.09%+177,999,900.00%+177,999,900.00%RGNXREGENXBIO+0.19%-15.87%+32.56%+10.71%+21.79%RLMDRelmada Therapeutics+6.00%-14.65%-21.25%-24.93%+763.19%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.70Moderate Buy$15.71457.24% UpsideNGENNervGen Pharma 2.83Moderate Buy$14.00686.52% UpsideRGNXREGENXBIO 2.62Moderate Buy$23.82130.35% UpsideRLMDRelmada Therapeutics 2.75Moderate Buy$12.00126.42% UpsideCurrent Analyst Ratings BreakdownLatest NGEN, ALT, RGNX, and RLMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2026RGNXREGENXBIO Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell7/13/2026NGENNervGen Pharma Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.007/1/2026RGNXREGENXBIO HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$26.006/24/2026ALTAltimmune Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/24/2026RGNXREGENXBIO HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$26.006/22/2026RGNXREGENXBIO Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$17.00 ➝ $18.006/22/2026RGNXREGENXBIO Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$27.00 ➝ $32.006/22/2026ALTAltimmune Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.006/18/2026RLMDRelmada Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/18/2026RLMDRelmada Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.006/18/2026RLMDRelmada Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$40K13,710.14N/AN/A$1.99 per share1.42NGENNervGen PharmaN/AN/AN/AN/AN/AN/ARGNXREGENXBIO$170.44M3.14N/AN/A$2.03 per share5.09RLMDRelmada TherapeuticsN/AN/AN/AN/A$1.18 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.09M-$0.93N/AN/AN/A-214,860.98%-42.57%-35.57%8/11/2026 (Estimated)NGENNervGen PharmaN/A-$0.09N/AN/AN/AN/AN/AN/AN/ARGNXREGENXBIO-$193.88M-$5.60N/AN/AN/A-330.23%-232.50%-61.02%8/6/2026 (Estimated)RLMDRelmada Therapeutics-$57.38M-$1.09N/AN/AN/AN/A-71.22%-64.46%8/6/2026 (Estimated)Latest NGEN, ALT, RGNX, and RLMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026ALTAltimmune-$0.15N/AN/AN/A$0.00 millionN/A8/6/2026Q2 2026RGNXREGENXBIO$0.2176N/AN/AN/A$106.91 millionN/A8/6/2026Q2 2026RLMDRelmada Therapeutics-$0.21N/AN/AN/AN/AN/A5/15/2026Q1 2026NGENNervGen Pharma-$0.07-$0.09-$0.02N/AN/AN/A5/14/2026Q1 2026RGNXREGENXBIO-$1.36-$1.72-$0.36-$1.72$25.84 million$6.39 million5/13/2026Q1 2026ALTAltimmune-$0.25-$0.18+$0.07-$0.18$0.00 millionN/A5/12/2026Q1 2026RLMDRelmada Therapeutics-$0.18-$0.22-$0.04-$0.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/ANGENNervGen PharmaN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmune0.1229.5629.56NGENNervGen PharmaN/AN/AN/ARGNXREGENXBION/A2.622.62RLMDRelmada TherapeuticsN/A18.2518.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%NGENNervGen PharmaN/ARGNXREGENXBIO88.08%RLMDRelmada Therapeutics45.24%Insider OwnershipCompanyInsider OwnershipALTAltimmune1.60%NGENNervGen Pharma5.80%RGNXREGENXBIO14.22%RLMDRelmada Therapeutics14.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune50194.47 million191.36 millionOptionableNGENNervGen PharmaN/A80.63 millionN/AN/ARGNXREGENXBIO37051.70 million44.35 millionOptionableRLMDRelmada Therapeutics10104.89 million89.68 millionOptionableNGEN, ALT, RGNX, and RLMD HeadlinesRecent News About These CompaniesRelmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Significant Growth in Short InterestJuly 17, 2026 | marketbeat.comRelmada Therapeutics (NASDAQ:RLMD) Stock Price Down 10.5% - Here's What HappenedJuly 16, 2026 | marketbeat.comRelmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026July 16, 2026 | globenewswire.comRelmada Therapeutics Joins Russell 2000 Index And Russell 3000 IndexJune 29, 2026 | benzinga.comRelmada Therapeutics Joins Russell 2000® and Russell 3000® IndexesJune 29, 2026 | globenewswire.comRelmada: NDV-01 Entering Phase 3 In NMIBC, But There's No Rush To Buy Stock TodayJune 19, 2026 | seekingalpha.comRelmada Therapeutics (RLMD): 10 Best Growth Stocks Under $30 to Buy NowJune 19, 2026 | finance.yahoo.comRelmada's cancer drug candidate sparks fresh bullish callJune 18, 2026 | msn.comRelmada Therapeutics IncJune 12, 2026 | edition.cnn.comRelmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone ProgramJune 11, 2026 | globenewswire.comRelmada Therapeutics Increases Authorized Shares After Shareholder VoteMay 28, 2026 | tipranks.comRelmada Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 28, 2026 | globenewswire.comRelmada Therapeutics Inc (RLMD) Q1 2026 Earnings Call Highlights: Strong Financial Position and ...May 13, 2026 | finance.yahoo.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2026 Earnings Call TranscriptMay 13, 2026 | insidermonkey.comRelmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comRelmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 12, 2026 | globenewswire.comRelmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026May 6, 2026 | globenewswire.comRelmada Therapeutics to Present NDV-01 Abstracts at AUA2026May 5, 2026 | globenewswire.comMizuho Securities Remains a Buy on Relmada Therapeutics (RLMD)April 16, 2026 | theglobeandmail.comDoes Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?April 13, 2026 | zacks.com5 Small Drug Stocks to Buy as Sector Recovery Gains StrengthApril 2, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Valuation Loses Altitude as AI Risks MountBy Jeffrey Neal Johnson | June 23, 2026The AI Chip Sell-Off Looks Scary, But the Real Story May Be LiquidityBy Jeffrey Neal Johnson | July 7, 2026Cerebras Systems, Inc: The Next Rags-to-Riches AI Story?By Thomas Hughes | June 25, 2026SpaceX Has Real Value—But These 3 Stocks Have Better Odds Right NowBy Bridget Bennett | June 28, 20262 Quantum Stocks That Could Challenge IonQ’s LeadershipBy Nathan Reiff | July 15, 2026NGEN, ALT, RGNX, and RLMD Company DescriptionsAltimmune NASDAQ:ALT$2.82 +0.01 (+0.36%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$2.85 +0.03 (+1.21%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.NervGen Pharma NASDAQ:NGEN$1.78 +0.05 (+2.89%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$1.76 -0.03 (-1.40%) As of 04:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.REGENXBIO NASDAQ:RGNX$10.34 +0.02 (+0.19%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$9.74 -0.60 (-5.84%) As of 04:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.Relmada Therapeutics NASDAQ:RLMD$5.30 +0.30 (+6.00%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$5.30 0.00 (0.00%) As of 04:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3M's Redemption Arc: Can Q2 Earnings Change the Narrative? Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of Earnings 3 Photonics Companies Making Quantum Tech Possible Confidence Is Back, But Earnings Show the Consumer Is Being Picky Industrial and Utility Giants Boost Dividends as Data Center Tailwinds Build IREN’s $2.8 Billion AI Contract Haul Changes the Stock’s Story AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 2 ETFs to Access the World's Best-Performing Stock Markets In 2026 Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
